- No public price. Enterprise sale.
- Not disclosed
- Not disclosed
- —
- —
- FR
Radiology
Therapixel MammoScreen
by Therapixel · FR
MammoScreen: breast cancer detection and density AI for 2D mammograms and tomosynthesis.
On this page
21/100Niche fit
- Regulatory & Compliance18/28
FDA cleared (7 K-numbers on record)
- Clinical Integration0/26
No EHR integrations listed
- Evidence Strength0/26
No peer-reviewed coverage
- Vendor & Market3/18
Seed-stage or unfunded
- Sentiment & Transparency2.5/14
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance18/18
FDA cleared (7 K-numbers on record)
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/14
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/8
None of the top-3 EHRs covered
- Bidirectional write-back0/4
No bidirectional write-back documented
- Peer-reviewed papers0/18
No peer-reviewed coverage
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal3/12
Seed-stage or unfunded
- Years in market0/6
Founded year not recorded
- Clinician sentiment (Reddit)0/9
No clinician sentiment data available
- Pricing transparency3/5
Pricing on request, no public amounts
MammoScreen: breast cancer detection and density AI for 2D mammograms and tomosynthesis.
No public price. Enterprise sale.
Bottom line
MammoScreen is breast cancer screening software from Therapixel of Nice, France. It reads 2D mammograms and tomosynthesis and has seven FDA 510(k) clearances since 2020, plus a CE mark. Breast imaging practices and health systems buy it, and the price is by quote only.
Who is Therapixel?
Therapixel calls itself one of the leading French software companies specializing in artificial intelligence applied to medical imaging. It says the software "helps in reading digital mammograms to detect and qualify suspicious tissue" and was trained by deep learning on "hundreds of thousands of cases" annotated by breast radiologists and confirmed by biopsy. A companion product, MammoScreen BD, assesses breast density.
Therapixel is at 455 Promenade des Anglais in Nice. Pierre Fillard and Olivier Clatz founded it in 2013, according to Tracxn. Total funding is about $22 million to $23 million (Tracxn $22.1 million, CB Insights $23.13 million), including a EUR 15 million Series B in May 2022. Investors listed on its site include Creazur, IT Translation, Omnes, M Capital and Region Sud Investissement.
Which FDA clearances does it hold?
The vendor says MammoScreen is "FDA-cleared and CE-marked", with CE 0297 class IIa and ISO 13485. FDA's 510(k) records list seven clearances for Therapixel, with these decision dates:
- K192854, March 2020, MammoScreen
- K211541, November 2021, MammoScreen 2.0
- K240301, August 2024, MammoScreen (3)
- K241561, October 2024, MammoScreen BD
- K243679, July 2025, MammoScreen (4)
- K243685, August 2025, MammoScreen BD
- K260714, June 2026, MammoScreen (5)
Where is it in use?
Mayo Clinic selected MammoScreen in June 2025. In April 2025 Onsite Women's Health announced plans to deploy it across more than 150 locations.
What studies are public?
Tracxn mentions the 2017 DREAM Challenge for mammography. In October 2022 Therapixel announced a prospective French study on the use of AI in second reading of screening mammograms.
How is it priced?
Therapixel sells to enterprise buyers and gives no public price.
The verdict
MammoScreen has a clearance record that spans six years and five software versions, plus deployments at Mayo Clinic and across Onsite's network. A breast imaging practice or health system that reads screening mammograms is the buyer. A practice that does not read mammograms has nothing to buy.
Editorial review last generated October 15, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | — | — | No public price. Enterprise sale. |
Source: vendor pricing page. Last checked October 15, 2026.
What deploys cleanly
Carries FDA 510(k), CE Mark (Class IIa, CE 0297, vendor-stated), ISO 13485 (vendor-stated) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.
Other radiology
See the full radiology ranking
Siemens Healthineers AI-Rad Companion
by Siemens Healthineers
AI-Rad Companion: Chest CT, Chest X-ray, Brain MR, Prostate MR and Organs RT (radiotherapy contouring) modules, delivered through teamplay.
No public price on the vendor page.|FDA 510(k) (multiple) / CE Mark (MDD/MDR. MDR status not verified)
GE HealthCare AI Suite
by GE HealthCare
Portfolio of separately cleared AI-enabled GE HealthCare devices and software, including AIR Recon DL, Sonic DL, Critical Care Suite, Caption AI and icobrain.
No public price. Products are sold with scanners or as scanner options, on enterprise quotes.|FDA 510(k) (multiple)
Aidoc
by Aidoc
Clinical AI platform (aiOS) with FDA-cleared triage, notification and quantification algorithms for radiology and neurovascular care.
Private offer only. No trial is stated.|FDA 510(k) (multiple) / EU MDR 2017/745
Viz.ai
by Viz.ai
Care coordination platform with FDA-cleared imaging AI for stroke, vascular and cardiac conditions.
No public price. Sold to health systems after a demo request.|FDA 510(k) (multiple) / FDA De Novo (ContaCT, Viz HCM)